| Cell line name |
Rh30rVCR10 |
|---|
| Accession |
CVCL_RR39 |
|---|
| Resource Identification Initiative |
To cite this cell line use: Rh30rVCR10 (RRID:CVCL_RR39) |
|---|
| Comments |
Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_28445; Vincristine (VCR).
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:3819; FOXO1 + HGNC; HGNC:8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line).
- Mutation; HGNC; HGNC:9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=19147553; PubMed=25749379).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Alveolar rhabdomyosarcoma (NCIt: C3749)
Alveolar rhabdomyosarcoma (ORDO: Orphanet_99756) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0041 (Rh30) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
17Y |
|---|
| Category |
Cancer cell line |
|---|
| Web pages |
Provider; RCCL; -; https://www.wass-michaelislab.org/rccl.php |
|---|
| Publications | PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Martin Michaelis, Florian Rothweiler, Denise Klassert, Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans-Wilhelm Doerr, Jindrich Cinatl Jr.;
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009) PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Martin Michaelis, Florian Rothweiler, Nadine Loschmann, Mohsen Sharifi, Taravat Ghafourian, Jindrich Cinatl Jr.;
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_RR39
|
|---|
| Encyclopedic resources |
Wikidata; Q54950342
|
|---|
| Entry history |
|---|
| Entry creation | 05-Mar-2018 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 15 |
|---|
